Cancer Drug Parity Act of 2025
In committee: it can still change before the session ends.
- Stage
- In committee
- Started in
- House
- Sponsors
- 30
- Latest action
- Jun 24, 2025
What it does
The Cancer Drug Parity Act of 2025 would require group health plans to provide cost-sharing for oral anticancer drugs that is no less favorable than for intravenously or injectable anticancer medications, ensuring patients taking pills at home face no higher out-of-pocket costs than those receiving treatment in a clinical setting. The bill applies to FDA-approved oral anticancer drugs deemed medically necessary or clinically appropriate by a treating physician and prohibits plans from circumventing the requirement by increasing costs, reclassifying benefits, or imposing stricter limits on oral drugs. It includes a GAO study to assess the law’s impact on patient costs and access, and the…
No official summary is available here. This one was written by AI from the bill’s text.
Where it stands
Introduced (Done)
Committee (Current step)
Floor (Not started)
Law (Not started)
What moved
Who is involved
Sponsors
The lawmakers who put their names on it, lead sponsors first.
- Glenn Grothman
- Andrea Salinas
- Becca Balint
- Brian Fitzpatrick
- Chris Pappas
- Chrissy Houlahan
- Deborah Ross
- Derek Schmidt
- Donald Davis
- Doris Matsui
- Ed Case
- Eleanor Norton
- Eugene Vindman
- Gus Bilirakis
- Gwen Moore
- Herbert Conaway
- Jamie Raskin
- Janelle Bynum
- Joe Neguse
- Joe Wilson
- John Garamendi
- Jonathan Jackson
- Joseph Morelle
- Julia Brownley
- Kathy Castor
- Robert Bresnahan
- Sharice Davids
- Suzanne Bonamici
- Timothy Kennedy
- William Keating
In the news
Reporting that may mention this subject. Possible matches are labeled.
Loading coverage…
Where it goes next
While a bill can still move, the questions are about people and money.